Jacob Chacko - 10 Jul 2023 Form 4 Insider Report for Oric Pharmaceuticals, Inc. (ORIC)

Role
President and CEO, Director
Signature
/s/ Christian Kuhlen, attorney-in-fact
Issuer symbol
ORIC
Transactions as of
10 Jul 2023
Net transactions value
-$125,499
Form type
4
Filing time
11 Jul 2023, 21:28:18 UTC
Previous filing
07 Jul 2023
Next filing
19 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORIC Common Stock Sale $84,212 -10,508 -1.3% $8.01 785,808 10 Jul 2023 Direct F1, F2
transaction ORIC Common Stock Sale $41,287 -5,156 -0.66% $8.01 780,652 11 Jul 2023 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 28, 2022.
F2 Represents the weighted average share price of an aggregate total of 10,508 shares sold in the price range of $8.00 to $8.05 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 Represents the weighted average share price of an aggregate total of 5,156 shares sold in the price range of $8.00 to $8.03 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.